Company News Summary
Imugene Doses First Patient in Vaxinia Phase 1 Trial
18 May 2022 | 08:38:00 | Associate analysts | Increase | Decrease | 
Original announcement: IMUGENE DOSES FIRST PATIENT IN VAXINIA PHASE 1 TRIAL
Imugene announced that the first patient was dosed in a Phase 1 clinical trial evaluating the safety of novel cancer-killing virus CF33-hNIS VAXINIA when used in people with advanced solid tumors. The City of Hope-developed oncolytic virus has been shown to shrink colon, lung, breast, ovarian and pancreatic cancer tumors in preclinical laboratory and animal models. Oncolytic virus therapy is made possible once viruses found in nature are genetically modified to infect, replicate in and kill cancer cells, while sparing healthy cells.
See more ASX300 News Announcements